Literature DB >> 21369866

[Biologics: from the "golden calf" to a "gold standard"?].

U Pleyer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21369866     DOI： 10.1007/s00347-010-2259-8

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  7 in total

Review 1.  [Anti-TNF-α treatment for uveitis. Analysis of the current situation].

Authors:  U Pleyer; F Mackensen; S Winterhalter; N Stübiger
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

2.  Treatment and visual prognosis in Behçet's disease.

Authors:  D Benezra; E Cohen
Journal:  Br J Ophthalmol       Date:  1986-08       Impact factor: 4.638

3.  Interferon-alpha 2b for refractory ocular Behçet's disease.

Authors:  E J Feron; A Rothova; P M van Hagen; G S Baarsma; M S Suttorp-Schulten
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

4.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

5.  Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.

Authors:  Yukiko Yamada; Sunao Sugita; Hiroyuki Tanaka; Koju Kamoi; Tatsushi Kawaguchi; Manabu Mochizuki
Journal:  Br J Ophthalmol       Date:  2009-08-18       Impact factor: 4.638

6.  Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.

Authors:  Lothar Krause; Andreas Altenburg; Uwe Pleyer; Anne-Katrin Köhler; Christos C Zouboulis; Michael H Foerster
Journal:  J Rheumatol       Date:  2008-04-15       Impact factor: 4.666

7.  GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.

Authors:  Claus Cursiefen; Felix Bock; Folkert K Horn; Friedrich E Kruse; Berthold Seitz; Vincent Borderie; Beatrice Früh; Michael A Thiel; Frank Wilhelm; Bernard Geudelin; Isabelle Descohand; Klaus-Peter Steuhl; Angela Hahn; Daniel Meller
Journal:  Ophthalmology       Date:  2009-07-29       Impact factor: 12.079
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.